Skip to main content
. Author manuscript; available in PMC: 2015 Jan 23.
Published in final edited form as: Neurobiol Dis. 2014 Sep 16;73:83–95. doi: 10.1016/j.nbd.2014.08.032

Fig. 4.

Fig. 4

Tau pathology in the contralateral hemisphere of mice injected with tau PFFs. (A) Sarkosyl soluble and insoluble brain fractions of the non-injected (left) hemisphere of an animal injected with K18-PL (25 μg) in the frontal cortex were analyzed for total and phosphorylated tau by ELISA. K18-PL injected animals show a clear increase in both total and phosphorylated insoluble tau when compared to buffer injected mice. This increase is observed for all three time points (1 m–2 m–3 m after K18-PL injection). No significant differences were observed in total and phosphorylated soluble tau. One-way Anova *p < 0.05 vs buffer (n = 63 m buffer, n = 101 m–2 m K18-PL, n = 73 m K18-PL). (B) AT8 IHC on sagittal brain sections of the contralateral hemisphere at 3 different levels (L −0.5; −2.0; −3.5 mm) shows the distribution of the tau pathology in the coronal plane. Scale bars: 2000 μm. (C) Quantification of the AT8 IHC in multiple brain areas at the 3 different levels indicates clear tau pathology throughout the whole contralateral hemisphere. One-way Anova *p < 0.05 vs buffer (n = 33 m buffer, n = 71 m K18-PL, n = 42 m K18-PL, n = 93 m K18-PL).